NCT02461719View on ClinicalTrials.gov

Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes

PHASE3CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Dry Eye Syndromes
Interventions
DRUG

CYPORIN N EYE DROPS 0.05%(TJCS eye drop)

1 drop twice/day for 12 weeks to both eyes.

DRUG

Restasis

1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.

Trial Locations (1)

Unknown

The Catholic University of Korea Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
lead

Taejoon Pharmaceutical Co., Ltd.

INDUSTRY

NCT02461719 - Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes | Biotech Hunter | Biotech Hunter